Certified Nurses Operating Room (CNOR) Practice Exam

Dantrolene is the specific antidote used in the management of malignant hyperthermia, a potentially life-threatening condition. The correct dosing protocol during a malignant hyperthermia crisis is to administer 2.5 mg/kg of dantrolene intravenously every 5 minutes until the symptoms of the hypermetabolic state subside, with a maximum total dose of 10 mg/kg.

This dosing regimen is designed to rapidly mitigate the symptoms of malignant hyperthermia, such as hyperthermia, muscle rigidity, and metabolic derangement. The potential for needing additional doses is critical, as the severity of the crisis can vary among patients. The maximum limit of 10 mg/kg ensures that the treatment is effective while also taking steps to minimize the risk of adverse effects related to dantrolene.

While other options may provide varying dosages, they do not conform to the established guidelines for managing a malignant hyperthermia crisis effectively. Understanding this dosing strategy is essential for ensuring timely and appropriate intervention in the operating room.